Guggenheim Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

by · The Cerbat Gem

Dianthus Therapeutics (NASDAQ:DNTH – Free Report) had its target price lifted by Guggenheim from $92.00 to $100.00 in a report released on Tuesday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock.

A number of other brokerages have also commented on DNTH. William Blair began coverage on Dianthus Therapeutics in a report on Wednesday, July 2nd. They set an “outperform” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday. Robert W. Baird upped their price target on Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Wedbush boosted their price objective on Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an “outperform” rating in a research note on Thursday, August 21st. Eight research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $60.67.

Get Our Latest Stock Analysis on DNTH

Dianthus Therapeutics Trading Down 0.1%

Shares of NASDAQ DNTH opened at $37.86 on Tuesday. Dianthus Therapeutics has a one year low of $13.36 and a one year high of $38.59. The firm has a market capitalization of $1.22 billion, a PE ratio of -11.65 and a beta of 1.46. The business has a 50-day moving average price of $22.65 and a two-hundred day moving average price of $20.43.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.87 million. Research analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current year.

Insider Activity

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total value of $700,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 8.15% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in DNTH. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $27,000. US Bancorp DE boosted its stake in shares of Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company’s stock worth $29,000 after acquiring an additional 1,510 shares during the period. BNP Paribas Financial Markets bought a new position in shares of Dianthus Therapeutics during the 4th quarter worth approximately $59,000. GAMMA Investing LLC boosted its stake in shares of Dianthus Therapeutics by 3,030.6% during the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock worth $70,000 after acquiring an additional 3,758 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after acquiring an additional 3,317 shares during the period. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

(Get Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

See Also